Möchten Sie immer auf dem neuesten Stand bleiben?

Dublin, Jan. 15, 2026 (GLOBE NEWSWIRE) -- The "Genetic Modification Therapies Clinical Applications: Gene Therapies, Genetically Modified Cell Therapies, RNA Therapies and Gene Editing" has been...

Phase 2 (~50% of patients evaluated to date at 12 months) shows 46% lesion growth reduction vs. controlThere are no OCU410-related serious adverse events reported across the Phase 1 and Phase 2...

MALVERN, Pa., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced...

Study supports favorable safety and tolerability profile and clinically meaningful functional and structural benefits in Stargardt disease patients MALVERN, Pa., Jan. 12, 2026 (GLOBE NEWSWIRE) --...

LEXINGTON, Mass. and AMSTERDAM, Jan. 09, 2026 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical...

MALVERN, Pa., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that...

Siren Biotechnology to Showcase Clinical-Stage Momentum at Major 2026 Healthcare Conferences

Paris, Jan. 06, 2026 (GLOBE NEWSWIRE) -- 88% reduction in urinary incontinence episodes in patients with neurogenic bladder sustained through 24 weeksGood tolerability maintainedEnrollment and...

Dublin, Jan. 05, 2026 (GLOBE NEWSWIRE) -- The "Gene Therapy R&D Market Report 2025-2035" has been added to ResearchAndMarkets.com's offering. Overall world revenue for the Gene Therapy...

Lexeo Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference